Antisense-Based Progerin Downregulation in HGPS-Like Patients' Cells

Area of Science:

• Molecular Biology
• Genetics
• Cell Biology

Background:

• Progeroid laminopathies, including Hutchinson-Gilford Progeria Syndrome (HGPS), are rare genetic disorders characterized by premature aging.
• These diseases stem from mutations in the LMNA gene, leading to aberrant splicing and the production of toxic truncated Prelamin A proteins like Progerin.
• Current therapeutic strategies for these conditions are limited.

Purpose of the Study:

• To investigate the efficacy of morpholino antisense oligonucleotides (AON) in correcting pathogenic LMNA splicing.
• To assess the reduction of Progerin and other truncated Prelamin A isoforms in cellular models of HGPS-like patients and Mandibuloacral Dysplasia type B (MAD-B).
• To establish a preclinical proof of principle for a personalized antisense oligonucleotide-based therapy.

Main Methods:

• Utilized morpholino antisense oligonucleotides (AON) designed to target and prevent aberrant splicing of the LMNA gene.
• Analyzed cellular models derived from HGPS-like patients and a MAD-B patient with a ZMPSTE24 mutation.
• Quantified the accumulation of Progerin, Prelamin A Δ35, and Prelamin A Δ90 isoforms at both transcriptional and protein levels.

Main Results:

• AON treatment significantly inhibited pathogenic LMNA splicing in HGPS-like patient cells.
• Marked reduction in the accumulation of Progerin and other truncated Prelamin A isoforms was observed.
• The study also included a MAD-B patient, demonstrating the potential broad applicability of the approach.

Conclusions:

• Morpholino antisense oligonucleotides represent a promising therapeutic strategy for progeroid laminopathies.
• The findings provide preclinical validation for a personalized antisense approach in HGPS-like and MAD-B patients.
• This approach may enable these patients to be considered for future clinical trials.